Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Ralinepag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ADVANCE CAPACITY 302; CAPACITY
- Sponsors United Therapeutics Corporation
- 19 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 02 Jun 2023 This trial has been discontinued in Germany (End Date: 08 Mar 2023), according to European Clinical Trials Database record.
- 17 May 2023 This trial has been discontinued in Poland according to European Clinical Trials Database record.